Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Overview

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Companies Involved in Therapeutics Development
Amgen Inc
Clayton Biotechnologies Inc
Immune Regulation Ltd
Intezyne Inc
Medical Guidance Systems LLC

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drug Profiles
HA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRL-201805 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IT-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit GRP78 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP78 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Dormant Products

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumel Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Product Development Milestones
Featured News & Press Releases
Apr 16, 2018: Intezyne To Showcase Novel Cancer Resistance Pathway Inhibitor IT-139’S Potential In Gastric Cancer At ChiBio Partnering Forum 2018 In Suzhou, PRC
Apr 13, 2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting
Apr 10, 2018: Combition of Checkpoint Inhibitors and Intezyne’s Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy
Mar 22, 2018: Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting
Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Desigtion for IT-139 in Pancreatic Cancer
Mar 31, 2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium
May 24, 2012: Niiki Pharma To Present Fil Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012
Feb 15, 2012: Niiki Pharma’s New Compound Found To Be Promising Against Cancer
Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339
Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339
Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents
Sep 20, 2011: Niiki Pharma Announces Positive Interim Data From Ongoing Clinical Trial Of Anti-Cancer Agent NKP-1339
Jun 01, 2011: Niiki Pharma To Present Interim Data From Phase I Study Of NKP-1339 At ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Clayton Biotechnologies Inc, H2 2019
Pipeline by Immune Regulation Ltd, H2 2019
Pipeline by Intezyne Inc, H2 2019
Pipeline by Medical Guidance Systems LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019